NCT06641648View on ClinicalTrials.gov

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) RelapseNK Cell

Interventions

DRUG

NK cell

Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER

NCT06641648 - A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. | Biotech Hunter | Biotech Hunter